NCT06321484View on ClinicalTrials.gov

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

October 31, 2031

Conditions
Platinum-resistant Ovarian CancerRecurrent Ovary CancerOvarian CancerOvarian CarcinomaOvarian Carcinoma, Recurrent
Interventions
BIOLOGICAL

Cytokine-Induced Memory-like Natural Killer Cells

Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.

DRUG

Interleukin 2

Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion

Trial Locations (2)

02215

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

ImmunityBio, Inc.
All Listed Sponsors
collaborator

ImmunityBio, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER